The Enzyme Experts
0
0
Resources
Company
Contact
X

Essential insights based on 3rd party publications:

Get the White Paper now
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X

Quantification Challenges of Chromatin — Associated Host Cell DNA:
An Underestimated Risk

  • Discover why host cell DNA quantities are often significantly underestimated.
  • Understand the limitation of conventional nucleases when degrading chromatin

Download the poster here
and get access to the
interactive Q&A

Get the Poster now
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X

The Largest Overlooked Cost Driver in Viral Vector Production

  • Up to half of produced vector is lost during Down Stream Processing(DSP)
  • The majority of manufacturing cost accumulates is DSP raw materials
  • Nuclease design decisions determine downstream economics

Download here and get access to the interactive Q&A

Get the Poster now
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Advanced Therapies

Salt-active nucleases for Viral Vector Manufacturing

Reduce cost-cell DNA and chromatin across physiological and high salt process conditions, with matched ELISA kits to support residual nuclease monitoring.

Select a step to explore
Cell Expansion
Vector Production
Harvest, Nuclease Treatment & Clarification
M-San • San HQ
Salt-active nucleases
Purification & Concentration
Analytics / QC
Matches ELISA Kits
Residual nucleases monitoring
Formulation & Fill
Step 1 of 6
Process step

Cell Expansion

Producer cells are expanded to support viral vector production. As cell density increases, cell stress and loss of viability can contribute host-cell DNA and chromatin to the process, creating an impurity burden that must be managed downstream.
Next solution point

Harvest, nuclease treatment & Clarification

Show me
Step 2 of 6
Process step

Vector Production

During viral vector production, the impurity burden continues to build alongside the vector product. Whether producing AAV, lentiviral vectors (LV) or using different production strategies, host-cell DNA and chromatin carries forward into harvest and downstream processing.
Next solution point

Harvest, nuclease treatment & Clarification

Show me
Step 3 of 6
Common bottleneck

Harvest, Nuclease Treatment & Clarification

The problem
Residual template DNA has to be removed after IVT, and conventional DNase I often needs high enzyme input to get there.
Drives the challenge of: RNA quality, cost per batch
The impact
- Regulatory and RNA quality risk
- More nuclease carried into purification
- Higher cost per batch

10x

less enzyme units than DNase I

>80%

lower modeled DNase cost per batch
The solution at this step
dsDNA-specific nuclease for post-IVT cleanup
~6 hr → <30 min
Sample preparation
  • Single-enzyme, one-incubation workflow
  • Compatible with tested therapeutically relevant modified uridines
  • Supports Urea-PAGE, Fragment Analysis and LC-MS workflows
View RiboClean™
Request early access
Step 4 of 6
Process step

Purification & Concentration

The vector is purified and concentrated while process impurities, including the nuclease, are removed. Reducing the DNA and chromatin burden earlier can support a more manageable purification feed.
Next bottleneck in your workflow

Analytics / QC

Show me
Step 5 of 6
Common bottleneck

RNA QC & Characterization

The problem
RNase H cap-analysis sample prep needs guide-oligo design, hybridization and multiple steps, and the readout typically relies on LC-MS.
Creates avoidable analytical time and complexity
The impact
- Approximately 6 hours of sample preparation
- Construct-specific guide-oligo workflow
- Slower analytical decisions
- Reliance on specialist instrumentation

~6 hr → <30 min

cap-efficiency sample preparation

>80%

lower modeled analytical cost vs RNase H
The solution at this step
Sequence-specific ssRNA restriction enzyme for cap-efficiency sample preparation
~6 hr → <30 min
Sample preparation
  • Single-enzyme, one-incubation workflow
  • Compatible with tested therapeutically relevant modified uridines
  • One digest, read by urea-PAGE, Bioanalyzer or LC-MS
View RiboCleave™
Request early access
Step 6 of 6
Process step

Formulation & Fill

Purified vector is prepared for formulation and fill. Upstream and downstream improvements that protect  recovery can translate into more usable output form each batch.
Workflow complete

Need help choosing a nuclease?

Request early access
The challenge

Challenges in viral vector manufacturing

Upstream viral vector production has been optimised extensively, yet significant losses can still occur downstream. Residual host-cell DNA and chromatin can increase viscosity, promote aggregation and complicate purification.

~2x

recovery yield improvement

>70%

lower nuclease-related costs

~40%

lower COGS per dose

Purity & Regulatory Risk

Residual host-cell DNA can persist as chromatin and may be underestimated by standard DNA analytics. This can increase QC burden and create uncertainty When demonstrating  impurity clearance at batch release.

Incomplete clearance & yield loss

Incomplete clearance & yield loss Undigested chromatin can drive aggregation, increase harvest viscosity and contribute to filter fouling, reducing vector recovery and effective downstream capacity.

Rising cost & manufacturing  complexity

Higher nuclease consumption, downstream bottlenecks and extended processing cycles can increase manufacturing cost and limit
scalability.
Salt-active nucleases and matched ELISA kits, optimised for the conditions in your process.
The solutions

Choose the nuclease ha fits your process conditions

Step 3 · harvest, high salt

San HQ

High-salt conditions. Higher recovery. Lower cost per dose.
~2x
recovery yield
>70%
lower nuclease costs
~40%
lower COGS per dose
  • Optimised for 400-700 mM  salt
  • Improves chromatin DNA clearance under de-aggregating conditions
  • Supports improved filterability and DSP robustness
+ SAN HQ ELISA SensoPlus for clearance testing
View product
See the data · Download poster
Step 3 ·harvest, physiological

M-San HQ

Physiological conditions. Faster digestion. Lower cost per dose.
Up to 4x
lower nuclease requirement
~2x
Recovery yield
~40%
lower cost per dose
  • Optimal activity ay 90-250 mM salt
  • Improves chromatin DNA clearance, LV filterability and DSP consistency
  • >70% lower nuclease costs
+ M-SAN HQ ELISA Kit for clearance testing
View product
See the data · Download poster
quality

Built for bioprocessing

Nuclease performance is only part of the manufacturing picture. ArcticZymes provides quality information and matched analytical tools to support implementation in viral vector processing workflows.

  • GMP-grade option available
  • ISO 13485 manufacturing context
  • Animal-origin-free raw material information
  • Traceability and quality documentation
  • Matched residual nuclease ELISA options